About AREXVY | AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

You are using an unsupported browser.

Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Sorry, your browser window is too small.

Some features of this site may not function properly. For optimal user experience, please view this site in a larger browser window.

For US Residents Prescribing Information Visit US Healthcare Professional Site Visit US HCP Site

USXF DTC Branded with Claims

Tell us what you are looking for in the search box.

SIGN UP TO LEARN MORE

ABOUT AREXVY

AREXVY is the first FDA-approved vaccine used to prevent lung and lower airway infection from respiratory syncytial virus (RSV) in people 60 years and older

Effective Against RSV

In a clinical study, AREXVY was:

OVER82^%

EFFECTIVE

in preventing lung and lower airway infection from RSV in people aged 60 years and older

OVER94^%

EFFECTIVE

in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease (COPD), chronic heart failure, advanced liver or kidney disease, or any chronic respiratory or pulmonary disease

For Those 60 Years and Older

AREXVY protects people 60 years and older—including those with certain health conditions (see above)—from lung and lower airway infections from RSV

AREXVY is available for people
aged 60 and older

AREXVY can be given at the same time as a quadrivalent flu vaccine

AREXVY is given as a single-dose shot

Find AREXVY near you GET AREXVY

How Does AREXVY Work?

AREXVY boosts your body’s protection against RSV, which can cause lower respiratory tract disease (LRTD). AREXVY is purposefully designed to stimulate the immune response to protect against RSV in people aged 60 years and older.

An Aging Immune System

As people reach older age, the immune system may weaken, and the body can have a more difficult time defending against infections like RSV.

Remember to get AREXVY before
the start of RSV season

Get questions to ask your doctor about AREXVYFAQs

ABOUT AREXVY

AREXVY is the first FDA-approved vaccine used to prevent lung and lower airway infection from respiratory syncytial virus (RSV) in people 60 years and older

Effective Against RSV

In a clinical study, AREXVY was:

OVER82^%

EFFECTIVE

in preventing lung and lower airway infection from RSV in people aged 60 years and older

OVER94^%

EFFECTIVE

in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease (COPD), chronic heart failure, advanced liver or kidney disease, or any chronic respiratory or pulmonary disease

For Those 60 Years and Older

AREXVY protects people 60 years and older—including those with certain health conditions (see above)—from lung and lower airway infections from RSV

AREXVY is available for people
aged 60 and older

AREXVY can be given at the same
time as a quadrivalent flu vaccine

AREXVY is given as a
single-dose shot

Find AREXVY near you

GET AREXVY

How Does AREXVY Work?

AREXVY boosts your body’s protection against RSV, which can cause lower respiratory tract disease (LRTD). AREXVY is purposefully designed to stimulate the immune response to protect against RSV in people aged 60 years and older.

An Aging Immune System

As people reach older age, the immune system may weaken, and the body can have a more difficult time defending against infections like RSV.

Remember to get AREXVY
before the start of RSV season

Get questions to ask your doctor
about AREXVY

FAQs

Protect Yourself
Against RSV

Protect Yourself Against RSV

GET AREXVY

See when and where you can get AREXVY.

GET VACCINE REMINDERS

Sign up for reminders about getting AREXVY.

STAY INFORMED

Sign up for more information about RSV and AREXVY.

Ask your doctor about

WHAT IS AREXVY & SAFETY INFO

What Is AREXVY?

What Is AREXVY?

AREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older.

Important Safety Information

You should not receive AREXVY if you are allergic to any of its ingredients

AREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older.

AREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older.

Important Safety Information

Important Safety Information - Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum.

You should not receive AREXVY if you are allergic to any of its ingredients
Fainting can happen after getting injectable vaccines, including AREXVY. Precautions should be taken to avoid injury due to fainting

You should not receive AREXVY if you are allergic to any of its ingredients
Fainting can happen after getting injectable vaccines, including AREXVY. Precautions should be taken to avoid injury due to fainting
Some people with weakened immune systems may have reduced immune responses to AREXVY
The most common side effects are injection site pain, fatigue, muscle pain, headache, and joint pain
Vaccination with AREXVY may not result in protection of all vaccine recipients
Ask your healthcare provider about the risks and benefits of AREXVY. Only a healthcare provider can decide if AREXVY is right for you

Please see full Prescribing Information.

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967.

Trademarks are owned by or licensed to the GSK group of companies.